Related Experiment Video

Updated: Jun 30, 2025

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

2.7K

Editorial Expression of Concern: Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage

Tong Cheng1, Anthony L Petraglia1, Zhang Li2

  • 1Department of Neurosurgery, Frank P. Smith Laboratory for Neuroscience and Neurosurgical Research, University of Rochester Medical Center, Rochester, 14642, New York, USA.

Nature Medicine
|March 21, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Improved Method for the Preparation of a Human Cell-based, Contact Model of the Blood-Brain Barrier
08:40

Improved Method for the Preparation of a Human Cell-based, Contact Model of the Blood-Brain Barrier

Published on: November 12, 2013

16.4K
Urokinase-type Plasminogen Activator-induced Mouse Back Pain Model
06:20

Urokinase-type Plasminogen Activator-induced Mouse Back Pain Model

Published on: September 1, 2023

992

Related Experiment Videos

Last Updated: Jun 30, 2025

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

2.7K
Improved Method for the Preparation of a Human Cell-based, Contact Model of the Blood-Brain Barrier
08:40

Improved Method for the Preparation of a Human Cell-based, Contact Model of the Blood-Brain Barrier

Published on: November 12, 2013

16.4K
Urokinase-type Plasminogen Activator-induced Mouse Back Pain Model
06:20

Urokinase-type Plasminogen Activator-induced Mouse Back Pain Model

Published on: September 1, 2023

992

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

692
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
692
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
The Blood-brain Barrier00:49

The Blood-brain Barrier

47.3K
Overview
47.3K

Articles linked to this work by shared authors, journal, and citation graph.

Elevated levels of circulating plasma sPDGFRβ in cognitively impaired APOE4 carriers.

GeroScience·2026

A Bivalent Protease-Activated Receptor-Derived Peptide Mimics Neuronal Anti-Apoptotic Activity of Activated Protein C.

Bioengineering (Basel, Switzerland)·2025

Automatic detection of arterial input function for brain DCE-MRI in multi-site cohorts.

Magnetic resonance in medicine·2025

Molecular signature and functional properties of human pluripotent stem cell-derived brain pericytes.

bioRxiv : the preprint server for biology·2025

Cerebral hypoperfusion, brain structural integrity, and cognitive impairment in older APOE4 carriers.

GeroScience·2025

The blood-brain barrier as a treatment target for neurodegenerative disorders.

Expert opinion on drug delivery·2025

Sex-specific biological aging clocks across organs and omics.

Nature medicine·2026

Factor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trial.

Nature medicine·2026

EBV reactivation priming of the peripheral immune system in multiple sclerosis relapse.

Nature medicine·2026

Liquid biopsy for early detection of pancreatic ductal adenocarcinoma.

Nature medicine·2026

Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial.

Nature medicine·2026

Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial.

Nature medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us